Increased proportions of PD-L1+ tumor cells in non-small cell lung cancer (NSCLC)[15], and PD-1+ lymphocytes in multiple myeloma[16] were observed at relapse compared to primary diagnosis. Here, CD274 is linked to non-small cell lung carcinoma.